Evidence map›Paper›PMID 42315594›Full record

ArticleScientific reports2026

Multi-pathogen serosurveillance in Tonga examining demographic correlates and geographic clustering of 17 pathogens.

Harriet L S Lawford, Ofa Tukia, Joseph Takai, Sarah Sheridan, Selina Ward, Holly Jian, Beatris Mario Martin, Reynold 'Ofanoa, Stefanie Vaccher, Fiona Angrisano and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Harriet L S LawfordUQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia. h.lawford@uq.edu.au.
Ofa TukiaPublic Health Division, Ministry of Health, Nuku'alofa, Tonga.
Joseph TakaiPublic Health Division, Ministry of Health, Nuku'alofa, Tonga.
Sarah SheridanUQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia.
Selina WardUQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia.
Holly JianUQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia.
Beatris Mario MartinUQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia.
Reynold 'OfanoaPublic Health Division, Ministry of Health, Nuku'alofa, Tonga.
Stefanie VaccherBurnet Institute, Melbourne, Australia.
Fiona AngrisanoBurnet Institute, Melbourne, Australia.
Leanne J RobinsonBurnet Institute, Melbourne, Australia.
Colleen L LauUQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia.

Funding

Australian National Health and Medical Research Council 1193826Australian National Health and Medical Research Council 2017630the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), which is funded at The Task Force for Global Health primarily by the Bill & Melinda Gates Foundation OPP1190754
6 · The paper itself

Abstract

Integrated serosurveillance enables concurrent assessment of population immunity to vaccine-preventable diseases (VPDs) and infectious pathogens. We aimed to estimate seroprevalence of antibodies (Abs) to 17 pathogens to provide insights to inform public health strategies to control and eliminate infectious diseases in Tonga. A targeted cross-sectional survey was conducted in May-July 2024 among participants aged ≥ 5 years from Tongatapu, Ha'apai, and Ongo Niuas. Dried blood spots were collected and assayed on a multiplex bead assay (MBA) containing 26 antigens from 17 pathogens. Seropositivity was defined using antigen-specific cut-offs. Associations with seropositivity were assessed, and geographic clustering was investigated. 1,786 of 1,787 (98.9%) participants (median age 19 years; 46% male) had valid MBA results. In our target population, LF Ab seropositivity increased with age, with high seroprevalence in Ha'apai (Wb123 Ab: 13.1%; Bm14 Ab: 8.8%). Dengue seroprevalence was > 90% among > 50-year-olds and were highest in Tongatapu. Seroprevalence for VPD was high; however, measles seroprevalence (86.1%) was below theoretical elimination thresholds despite historically high vaccination coverage. Geographic clustering was significant (p < 0.01) for most pathogens, with strongest clustering seen at village-level. Clear demographic and geographic correlates of seroprevalence in this target population highlight focal transmission and potential immunity gaps. MBA platforms offer a cost-effective tool to support targeted elimination strategies and vaccination campaigns in the Pacific.

Indexed as

Communicable DiseasesAdolescentAdultAntibodies, ViralChildChild, PreschoolCross-Sectional StudiesFemaleHumansMaleMiddle AgedSeroepidemiologic StudiesTongaYoung AdultAntibodies, ViralEliminationInfectious diseasesIntegrated serosurveillanceMultiplex bead assaysTonga

Identifiers

PMID42315594
PMCPMC13550525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.